Cronos Stock: Win Big Or Lose All
I maintain a 'strong buy' rating for Cronos, despite regulatory headwinds, due to its strong fundamentals and potential for multibagger returns. Cronos has shown positive progress with a robust cash buffer, 35% revenue growth, reduced EBITDA losses, and positive operating cash flows in FY 2024. International expansion, strategic investments, and a focus on R&D are key drivers for Cronos' sustained top-line growth and market diversification.
Cronos Group Inc. (CRON) 37th Annual Roth Conference (Transcript)
Cronos Group Inc. (NASDAQ:CRON ) 37th Annual Roth Conference March 17, 2025 4:00 PM ET Company Participants Mike Gorenstein - Chairman, President and Chief Executive Officer Conference Call Participants Bill Kirk - Roth Capital Partners Bill Kirk Awesome. Good afternoon everybody.
Cronos Reports Improved Q4-2024 Financials With Revenues From GrowCo
Cronos reported 27% increase in revenues YOY for Q4-2024. The company is now reporting revenues from its 50% ownership of GrowCo. The company reported increasing profits and free cash flow for the quarter.
Cronos Q4 Sales Jump 27% On Higher Cannabis Flower And Extract Sales, Reports Improved Profitability
On Thursday, Cronos Group Inc CRON reported fourth-quarter sales of $30.3 million, up from $23.92 million, missing the consensus of $34.95 million.
Cronos Group Inc. (CRON) Q4 2024 Earnings Call Transcript
Cronos Group Inc. (NASDAQ:CRON ) Q4 2024 Results Conference Call February 27, 2025 8:30 AM ET Company Participants Anna Shlimak - Chief Strategy Officer Mike Gorenstein - Chairman, President and Chief Executive Officer James Holm - Chief Financial Officer Operator Good morning. My name is Antoine, and I will be your conference operator today.
Cronos Group (CRON) Reports Q4 Loss, Misses Revenue Estimates
Cronos Group (CRON) came out with a quarterly loss of $0.01 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.05 per share a year ago.
Why Cronos Group Stock Popped 9% Today
Cronos stock just went up -- a lot. Maybe it's time to sell?
Cronos Group Inc. (CRON) Q3 2024 Earnings Call Transcript
Cronos Group Inc. (NASDAQ:CRON ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Anna Shlimak - Chief Strategy Officer Mike Gorenstein - Chairman, President and CEO James Holm - CFO Conference Call Participants Matt Bottomley - Canaccord Genuity Bill Kirk - Roth Capital Partners Operator Good morning. My name is Brianna and I will be your conference operator today.
3 Marijuana Stocks To Watch On September 11th
Over the last several days some marijuana stocks have begun to pick up in momentum. There have been several attempts to show good faith in the legalization efforts for cannabis markets across the USA. Recently Trump has shown his support for legal cannabis in Florida under the right conditions. From this news, more people began to speculate that Trump's support can mean big things for legal cannabis. In addition to fueling more profitable trading in the hopes of better reform measures.
Why Cronos Group Stock Is Sinking Today
The DEA scheduled a public meeting about cannabis rescheduling for Dec. 2, 2024. It's possible that cannabis won't be rescheduled before the next president takes office, if at all.
Buy Cronos Stock Before It Surges Higher
Initiating coverage on Cronos stock with a "Strong Buy" rating. Cannabis industry tailwinds, conservative growth approach, and geographic expansion support Cronos' growth acceleration and EBITDA margin improvement. A strong cash buffer of $848 million coupled with a zero-debt balance sheet provides flexibility for organic and acquisition-driven growth.
7 Growth Stocks to Buy on Corrections for 3X Returns by 2026
The S&P 500 index touched highs of 5,670 in July. Over the last one month, the index movement has been volatile with a downward bias.
